| Micro-channel |
 |
|
|
|
|
|
| |
| The first three varieties of blood products to the market!How fast are they growing? |
| |
| Author：中國(guó)銘鉉 企劃部 Release Time：2017-9-1 10:55:29 Number Browse：947 |
| |
In 2016, China issued 3,949 vaccines for the vaccine, with a total of 646 million people, according to the annual report of the pharmaceutical network on September 1.Blood products 4025 batches, approximately 5927.8 million bottles;Blood screening reagent 836 batches, about 878 million people.The annual report data can be used to understand the market demand and supply situation of domestic vaccines and blood products.
In 2016, the domestic market of hospital blood sample in the top three products are human blood albumin, human immunoglobulin, restructuring Ⅷ clotting factors and the overall market to show high growth momentum.It is noteworthy that the sales of human blood albumin amounted to 23.1 billion yuan and the sample hospital was ranked no.1.People's immunoglobulin sales were 1.04 billion yuan, and the sample hospital was ranked 22nd, which is more than 2 billion yuan and 1 billion yuan of products in the domestic blood products market.
In 2017, some blood products in the new health care catalogue will increase the indications, and the industry will continue to grow in the future.The following samples of domestic hospital data, analyzed human blood albumin, human immunoglobulin, human recombinant coagulation factor Ⅷ three blood products in the market situation.
Blood products are growing fast
Sales in 2016:4.300 billion yuan, up 21.6% year on year
Blood products are made from human blood separation and extraction, and are used in patients with different conditions.The main categories of blood products include: human blood albumin, immunoglobulin and coagulation, which are the most common types of coagulants.From the development of the domestic blood products industry, the domestic blood products market is greatly affected by the policy, mainly dominated by the government, and as the demand is expanding, the domestic blood products market is still in a tight market.
Samples according to the domestic hospital statistics, 2005 samples of hospital blood products sales of 750 million yuan, 2016 samples of hospital blood products sales as high as 4.3 billion yuan, the same period year-on-year growth of 21.6%, the overall market growth 5.8 times;The compound growth rate was 17.3% from 2005 to 2016, which was well above the industry level.Blood products in 2005-2008 have seen a significant downturn, but since 2009, they have maintained high growth for eight consecutive years.
In 2016, entered the hospital blood products a total of 14 samples, the top ten products were human blood albumin (sales of 2.31 billion yuan, the same below), immunoglobulin (1.04 billion yuan), human recombinant coagulation factor Ⅷ (270 million yuan), fibrinogen (170 million yuan), clotting factor Ⅷ (100 million yuan), and hepatitis b immune globulin (97.02 million yuan), fibrin glue (95.11 million yuan), human recombinant coagulation factor Ⅶ a (53.97 million yuan), tetanus immunoglobulin (523.6 billion yuan), prothrombin complex 4825 (one hundred million yuan).Among them, the human blood albumin (53.8%), human immunoglobulin (24.3%), human recombinant coagulation factor Ⅷ accounted for 6.3%, top three products accounted for 84.3% of the overall market, human blood albumin still occupy half of the domestic market of blood products.
Rapid growth in the top ten products are: the human blood albumin (year-on-year growth of 14.6%, the same below), immunoglobulin (19.7%), human recombinant coagulation factor Ⅷ (57.5%), fibrinogen (140.7%), and hepatitis b immune globulin (28.5%), fibrin glue (27.8%), human recombinant coagulation factor Ⅶ a (12.0%), tetanus immunoglobulin (25.9%).In addition, rabies immunoglobulins, despite sales in 11 places, were up 98.8% year on year, and the performance was outstanding.It can be seen that, with the growth rate of blood products below 10% in the whole pharmaceutical industry, the growth rate of many products remains high, which reflects the rigid demand and rapid growth of the blood products market.
Hospital, 2016 samples of blood products involved in the production of enterprises has nearly 30, among them, the top ten are: Baxter (Baxter, sales of 660 million yuan, the same below), Grifols (510 million yuan), Sanofi (Sanofi, 460 million dollars), shandong tai bang (340 million yuan), ZLB Behring AG (310 million yuan), sichuan yuanda shu Yang pharmaceutical (270 million yuan), Shanghai (240 million yuan), alex's aperture (220 million yuan), henan xinxiang China Bayer (Bayer, $180 million), guizhou's bond (170 million yuan), the top 10 enterprises occupy 77.9% of the share.Among the top 10 companies, there are five local and foreign companies.Among them, the share of foreign companies accounted for 62.9 percent, while local enterprises accounted for 37.1 percent.The market of blood products has been developing over the years, the advantages of foreign companies have gradually narrowed, and the market concentration of local enterprises has increased year by year.
Human blood albumin top spot is difficult to regret
Sales in 2016:23.1 billion yuan, up 14.6% year on year
Human blood albumin, also known as serum albumin, is the most commonly used blood products.The product can be used as a therapeutic medicine for the plasma capacity, and can be used as a supplement for injection drug prescription.Because of its wide clinical application, it is one of the few blood products permitted by the state.In recent years, human blood albumin has been a popular breed in the domestic drug market.In 2011-2014, the product ranked in the top three in the domestic sample hospital, and the top three in 2015 and 2016.
Samples according to the domestic hospital statistics, 2005 samples of hospital human blood albumin sales of 490 million yuan, 2016 sales of 2016 yuan, year-on-year growth of 14.6% over the same, the overall market growth 4.7 times;The compound growth rate was 15.0% from 2005 to 2016.Since listing, human blood albumin is in short supply for a long time, mainly imports, as domestic began to restrict imports human blood albumin, local blood products enterprises gradually strengthened.Since 2009, domestic blood albumin market has been on the rise.In 2017, the new medical insurance directory and new indications, human blood albumin payment scope is limited to the rescue, severe or chest water caused by liver cirrhosis, cancer patients with less than 30 g/L, and albumin has let go, for the domestic academic promotion ability of the enterprise added motivation.
In 2016, the sample hospitals involved in human blood albumin production enterprises have 25, among them, the enterprise is the top five were: Baxter (Baxter, sales of 600 million yuan, the same below), Grifols (510 million yuan), Sanofi (Sanofi, 460 million dollars), ZLB Behring AG (310 million yuan), shandong tai bang biological products (95.54 million yuan), the first five companies occupy 84.8% of the share.In the whole market, the import enterprises occupy the absolute advantage, the domestic variety of the obvious promotion.Domestic enterprises such as shandong taibang biological products, guizhou taibang biology, chengdu rongsheng pharmaceutical, sichuan great shu Yang and others occupy a place in the market of human blood albumin.
Human immunoglobulins are the most important
Sales in 2016:1.04 billion yuan, up 19.7% year on year
Immunoglobulin is mainly divided into human immunoglobulin and specific human immunoglobulin.In 2016, the market for human immunoglobulin was more than 1 billion yuan and the sample hospital was ranked 22nd.In the specific human immunoglobulins, hepatitis b immunoglobulin sales were 97.02 million yuan, up 28.5% year on year.The sales of tetanus immunoglobulin were 523.6 million yuan, up 201.9 percent year on year.The sales of rabies immunoglobulin sales were 46.49 million yuan, up 98.8% year on year.The three specific human immunoglobulin products market is relatively small, but the growth rate is more prominent.
Samples according to the domestic hospital statistics, 2005 hospital immunoglobulin were generated sales of 140 million yuan, 2016 sales of 2016 yuan, year-on-year growth of 19.7% over the same, the overall market growth 7.5 times;The compound growth rate was 20.0% in 2005-2016.In 2017, the new edition of the health care catalogue has been adjusted for the application of human immunoglobulins, in which the static injection of immunoglobulin is limited to the deficiency of primary immunoglobulin.Neonatal septicaemia;Severe primary immune thrombocytopenia;Kawasaki disease;Systemic myasthenia gravis;Six indications of acute greenbarre syndrome.The new adaptive immunoglobulin is an opportunity for market academic promotion and sales volume.
In 2016, sample hospital people immunoglobulin production enterprises have 23 involved, including the top five companies are: shandong tai state biological products (sales of 180 million yuan, the same below), sichuan yuanda shu Yang pharmaceutical (160 million yuan), henan xinxiang China aperture (120 million yuan), guizhou's state biological products (104 million yuan), biological pharmaceutical (85.47 million yuan), the same way occupies 62.4% share of the top five enterprises.Among the above-mentioned enterprises, the growth of the rapid growth of henan xinxiang huaran organism, guizhou taibang biological products, tonglu biopharmaceuticals, the growth rate of 3 enterprises exceeded 50.0%, the market performance was not bad.At present, there are no importers of immunoglobulin, and the market competition is more moderate.
Human recombinant coagulation factor Ⅷ appears
Sales in 2016:270 million yuan, a year-on-year increase of 57.5%
Clotting co-stimulating variety is more, the main products are human recombinant coagulation factor Ⅷ, fibrinogen, human clotting factor Ⅷ, human fibrin glue, human recombinant coagulation factor Ⅶ a, prothrombin complex, human fibrin glue, histamine immunoglobulin, restructuring clotting factor IX.Such products in 2016, the top five are: human recombinant coagulation factor Ⅷ (sales of 270 million yuan, the same below), fibrinogen (170 million yuan), clotting factor Ⅷ (100 million yuan), fibrin glue (95.11 million yuan), human recombinant coagulation factor Ⅶ (53.97 million yuan), a top five products in addition to blood coagulation factor Ⅷ sales declined, the other four growth products is more obvious.
According to the domestic sample hospital statistics, 2008 samples of hospital human recombinant coagulation factor Ⅷ generated sales of 3.05 million yuan, 2016 annual sales of 2016 yuan, year-on-year growth of 57.5% over the same, the overall market growth nearly 50 times;The compound growth rate was 74.8% in 2009 and 2016.Restructuring in 2009-2015 people, in fact, clotting factor Ⅷ market has been relatively mild, in 2016, the market is growing rapidly, become the top of the list of blood products.In 2017, the new medical insurance directory of human recombinant coagulation factor Ⅷ scope have been adjusted, children with hemophilia a limits;Adult a hemophilia is used when hemophilia is limited to bleeding.Human recombinant coagulation factor Ⅷ as hemophilia replacement therapy effects of the product, its supply tension has caused wide public concern.
In 2016, the hospital restructuring clotting factors were Ⅷ involves three production enterprises, all for foreign companies.Bayer (Bayer) of "worship the sarkozy" sales of 180 million yuan, Baxter (Baxter) "best for" sales of 64.01 million yuan, Wyeth (Wyeth) "Ren Jie" sales of 30.52 million yuan, the market share of 65.1%, 23.7% and 11.3% respectively.Bayer's "baike" market has been one of the best, with more than 60 per cent of the market.
Bayer injected with human recombinant coagulation factor Ⅷ worship "sarkozy" approved to enter China market in 2007, the drug is the first domestic listed gene recombinant coagulation factor Ⅷ, for hemostatic medicines market in one of the faster growing species.
Conclusion the < < <
Blood products is special medicine has important clinical value in our country, at present our country blood products per capita consumption is still far lower than international level, with the improvement of our country medical treatment level and the improvement of the health care system, clinical use of blood products continue to increase, with the help of the new health care increase factors such as blood products catalog indications, the future market capacity will continue to presents the fast growth the tendency.
|
| |
Previous article：27 major varieties of primary hospitals are not reimbursed!Thrombus, clear spirit...
Next article：Pharmaceutical companies enter the top 500 manufacturing industries in China
|
| |
|
|
